← Back to Search

64Cu-SAR-bisPSMA for Prostate Cancer (COBRA Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Clarity Pharmaceuticals Ltd
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 0 (1- 4 hours)
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new imaging agent called 64Cu-SAR-bisPSMA. It helps doctors see if prostate cancer has come back in patients who have already been treated. The agent works by attaching to cancer cells and making them visible on PET/CT scans.

Eligible Conditions
  • Prostate Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 0 (1- 4 hours) post injection
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 0 (1- 4 hours) post injection for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Participant-level CDR- Day 1
Participant-level Correct Detection Rate (CDR)- Day 0
Region-level PPV- Day 1
+2 more
Secondary study objectives
Biodistribution of 64Cu-SAR-bisPSMA- SUVmax
Biodistribution of 64Cu-SAR-bisPSMA- SUVmean
Biodistribution of 64Cu-SAR-bisPSMA- SUVr
+7 more

Side effects data

From 2023 Phase 1 & 2 trial • 52 Patients • NCT05249127
2%
urosepsis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Safety Analysis Set

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: 64Cu-SAR-bisPSMAExperimental Treatment1 Intervention
Patients will receive a single administration of 200 megabecquerels (MBq) of 64Cu-SAR-bisPSMA.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
64Cu-SAR-bisPSMA
2022
Completed Phase 2
~90

Find a Location

Who is running the clinical trial?

Clarity Pharmaceuticals LtdLead Sponsor
10 Previous Clinical Trials
690 Total Patients Enrolled
2 Trials studying Prostate Cancer
413 Patients Enrolled for Prostate Cancer
Othon GervasioStudy DirectorClarity Pharmaceuticals
~15 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top